secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001558370-23-013191
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q2 net revenue $135.5M (+10% YoY); GAAP net income $13.0M vs loss; authorizes $50M buyback
--------------------------------------------------------------------------------

- Q2 GAAP net income $13.0M ($0.34 diluted EPS) vs GAAP net loss of $5.2M a year ago; adjusted EBITDA $85.8M, up 21% YoY.
- Board authorized $50M accelerated share repurchase program; reaffirmed FY2023 guidance product revenue $565-580M, adjusted EBITDA $355-370M.
- Xtampza ER revenue grew 24% YoY to $41.2M; Nucynta franchise revenue up 8% YoY to $47.3M; Belbuca prescriptions up 3.5% QoQ.
- FDA approved Nucynta for children ages 6+; pediatric extension could extend exclusivity to Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/0001558370-23-013191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/coll-20230803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer